DeepNewz Markets

Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B

Oct 24, 2024, 12:51 PM

Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.

View original story

Markets

Will Moldova approve gene editing trials for other diseases by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Yes • 50%

No • 50%

Official announcements from the Moldovan government or health authorities

Will Moldova report adverse effects from PBGENE-HBV trial by end of 2024?

Moldova•Precision BioSciences

Resolution / Starting Odds

No • 50%

Yes • 50%

Official statements from Moldova's health authorities or Precision BioSciences

Will PBGENE-HBV trial expand to other countries by mid-2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Yes • 50%

No • 50%

Announcements from Precision BioSciences or regulatory approvals in new countries

Will PBGENE-HBV trial meet its primary endpoint by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Yes • 50%

No • 50%

Official trial results published by Precision BioSciences or authoritative medical journals

Will PBGENE-HBV trial show significant HBV DNA reduction by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

No • 50%

Yes • 50%

Published results in medical journals or official press releases from Precision BioSciences

Will Precision BioSciences' PBGENE-HBV trial complete Phase 1 by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Yes • 50%

No • 50%

Official announcements from Precision BioSciences or clinical trial registries

How many patients will be enrolled in PBGENE-HBV trial by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

50 to 100 • 25%

Less than 50 • 25%

More than 200 • 25%

101 to 200 • 25%

Clinical trial registries or official reports from Precision BioSciences

How will Precision BioSciences' stock react to PBGENE-HBV trial results?

Moldova•Precision BioSciences

Resolution / Starting Odds

Stock price remains stable • 25%

Stock price increases by less than 10% • 25%

Stock price decreases • 25%

Stock price increases by more than 10% • 25%

Stock market data for Precision BioSciences

What will be the EU's decision on PBGENE-HBV further trials by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Rejected • 25%

Pending decision • 25%

Approved without conditions • 25%

Approved with conditions • 25%

Announcements from the European Medicines Agency or Precision BioSciences

What will be the outcome of PBGENE-HBV trial's primary endpoint by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Partially met primary endpoint • 25%

Met primary endpoint • 25%

Trial inconclusive • 25%

Did not meet primary endpoint • 25%

Published results in medical journals or official press releases from Precision BioSciences

What will be the outcome of the first phase of PBGENE-HBV trial by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

Successful with minor adverse effects • 25%

Successful with no adverse effects • 25%

Trial halted due to safety concerns • 25%

Unsuccessful • 25%

Official trial results published by Precision BioSciences

Which country will approve PBGENE-HBV trial next by end of 2025?

Moldova•Precision BioSciences

Resolution / Starting Odds

China • 25%

Other • 25%

United States • 25%

European Union • 25%

Official announcements from Precision BioSciences or relevant health authorities

Looking for markets...